EQ
Equillium, Inc. NCM$2.12
Mkt Cap $134.0M
52w Low $0.27
76.1% of range
52w High $2.70
50d MA $1.89
200d MA $1.35
P/E (TTM)
—
Forward P/E
-8.48x
EPS (TTM)
$-0.39
Forward EPS
$-0.25
Price/Book
4.56x
Book Value
$0.47
Revenue TTM
—
Gross Margin
0.0%
Oper. Margin
0.0%
Net Margin
0.0%
ROE
-94.0%
ROA
-51.4%
Debt/Equity
2.51x
Current Ratio
10.58x
Div Yield
—
Div Rate
—
Payout Ratio
0.0%
Beta
1.7430
Shares Out
$63.0M
Float
$31.0M
Short Ratio
4.42x
Short % Float
5.5%
Inst. Held
60.9%
Insider Held
20.1%
Avg Volume
504,737
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Ret 1d | Alpha 1m |
|---|---|---|---|---|---|---|
| Apr 23, 2026 | Oppenheimer | Initiates | Outperform | $7 | — | — |
About
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as wel…
Data updated apr 21, 2026 3:58pm
· Source: Yahoo Finance